A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Public ClinicalTrials.gov record NCT06722235. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it. The participants will be treated with mezagitamab for up to 6 months. During the study, participants will visit their study clinic several times. Participants who complete the TAK-079-3002 study or do not have any response to study treatment by week 16 (according to study criteria) will be given the opportunity to participate in a continuation study to receive open label mezagitamab (if they are eligible and the site is able to open the continuation study).
Study identification
- NCT ID
- NCT06722235
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 171 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2025
- Primary completion
- Mar 15, 2028
- Completion
- Mar 15, 2028
- Last update posted
- Aug 6, 2026
2025 – 2028
United States locations
- U.S. sites
- 25
- U.S. states
- 20
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Genesis Cancer and Blood Institute - SCRI | Hot Springs | Arkansas | 71913 | Not yet recruiting |
| USC Norris Comprehensive Cancer Center - Keck Medicine of USC | Los Angeles | California | 90033 | Recruiting |
| University of California San Diego Center for Bleeding and Clotting Disorders | San Diego | California | 92121 | Not yet recruiting |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | Withdrawn |
| Georgetown University Medical Center - Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20007 | Recruiting |
| Emory University | Atlanta | Georgia | 30308 | Recruiting |
| Innovative Hematology, Inc. | Indianapolis | Indiana | 46260 | Not yet recruiting |
| The University of Iowa | Iowa City | Iowa | 52242 | Recruiting |
| University Of Louisville Brown Cancer Center | Louisville | Kentucky | 40202 | Recruiting |
| American Oncology Partners of Maryland, PA | Bethesda | Maryland | 20817 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| University of Massachusetts Chan Medical School | Worcester | Massachusetts | 01655 | Recruiting |
| MidAmerica Cancer Center | Kansas City | Missouri | 64132 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 28204 | Not yet recruiting |
| Montefiore Medical Center | The Bronx | New York | 10461 | Not yet recruiting |
| Duke University Hospital | Durham | North Carolina | 27710 | Recruiting |
| East Carolina University | Greenville | North Carolina | 27837 | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Not yet recruiting |
| Oregon Health & Science University | Portland | Oregon | 97239 | Recruiting |
| Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Lewis Katz School of Medicine at Temple University | Philadelphia | Pennsylvania | 19140 | Recruiting |
| Baylor College of Medicine | Houston | Texas | 77030 | Recruiting |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | Recruiting |
| University of Washingto | Seattle | Washington | 98109 | Not yet recruiting |
| Versiti Wisconsin, Inc | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06722235, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06722235 live on ClinicalTrials.gov.